triiodothyronine has been researched along with Demyelinating Diseases in 11 studies
Triiodothyronine: A T3 thyroid hormone normally synthesized and secreted by the thyroid gland in much smaller quantities than thyroxine (T4). Most T3 is derived from peripheral monodeiodination of T4 at the 5' position of the outer ring of the iodothyronine nucleus. The hormone finally delivered and used by the tissues is mainly T3.
3,3',5-triiodo-L-thyronine : An iodothyronine compound having iodo substituents at the 3-, 3'- and 5-positions. Although some is produced in the thyroid, most of the 3,3',5-triiodo-L-thyronine in the body is generated by mono-deiodination of L-thyroxine in the peripheral tissues. Its metabolic activity is about 3 to 5 times that of L-thyroxine. The sodium salt is used in the treatment of hypothyroidism.
Demyelinating Diseases: Diseases characterized by loss or dysfunction of myelin in the central or peripheral nervous system.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Chronic demyelination and plaque formation in multiple sclerosis is accompanied by persisting astrogliosis, negatively influencing central nervous system recovery and remyelination." | 1.43 | Regulatory effect of triiodothyronine on brain myelination and astrogliosis after cuprizone-induced demyelination in mice. ( Azimzadeh, M; Beyer, C; Clarner, T; Golestani, A; Kashani, IR; Omidi, N; Pasbakhsh, P; Zendedel, A, 2016) |
| "Demyelination was induced by two weeks cuprizone treatment." | 1.43 | The effect of triiodothyronine on maturation and differentiation of oligodendrocyte progenitor cells during remyelination following induced demyelination in male albino rat. ( Abd El-Kader, M; Abdelaziz, H; El-Shahat, M; El-Tahry, H; Marei, HE; Shams, A, 2016) |
| "In summary, we describe an in vivo demyelination/remyelination paradigm that can be powered to determine efficacy of therapies that enhance white matter and cortical remyelination." | 1.43 | A mouse model for testing remyelinating therapies. ( Bai, CB; Benson, E; Dutta, R; Edberg, D; Kidd, G; Macklin, WB; Medicetty, S; Roholt, A; Sun, S; Trapp, B, 2016) |
| "The changes triggered by demyelination were reverted after T3 administration, suggesting that THs could be regulating the emergence of remyelinating oligodendrocytes from the pool of proliferating cells residing in the SVZ." | 1.35 | Thyroid hormones promote differentiation of oligodendrocyte progenitor cells and improve remyelination after cuprizone-induced demyelination. ( Franco, PG; Pasquini, JM; Silvestroff, L; Soto, EF, 2008) |
| "During demyelination, myelin protein mRNA levels decreased to approximately 50% of control cultures and returned to normal during remyelination." | 1.28 | Myelin gene expression during demyelination and remyelination in aggregating brain cell cultures. ( Comte, V; Honegger, P; Matthieu, JM; Tosic, M, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (18.18) | 18.2507 |
| 2000's | 4 (36.36) | 29.6817 |
| 2010's | 4 (36.36) | 24.3611 |
| 2020's | 1 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| Chaudhary, P | 1 |
| Marracci, GH | 1 |
| Calkins, E | 1 |
| Pocius, E | 1 |
| Bensen, AL | 1 |
| Scanlan, TS | 1 |
| Emery, B | 1 |
| Bourdette, DN | 1 |
| Zendedel, A | 1 |
| Kashani, IR | 1 |
| Azimzadeh, M | 1 |
| Pasbakhsh, P | 1 |
| Omidi, N | 1 |
| Golestani, A | 1 |
| Beyer, C | 1 |
| Clarner, T | 1 |
| El-Tahry, H | 1 |
| Marei, HE | 1 |
| Shams, A | 1 |
| El-Shahat, M | 1 |
| Abdelaziz, H | 1 |
| Abd El-Kader, M | 1 |
| Bai, CB | 1 |
| Sun, S | 1 |
| Roholt, A | 1 |
| Benson, E | 1 |
| Edberg, D | 1 |
| Medicetty, S | 1 |
| Dutta, R | 1 |
| Kidd, G | 1 |
| Macklin, WB | 1 |
| Trapp, B | 1 |
| Franco, PG | 1 |
| Silvestroff, L | 1 |
| Soto, EF | 1 |
| Pasquini, JM | 1 |
| Harsan, LA | 1 |
| Steibel, J | 1 |
| Zaremba, A | 1 |
| Agin, A | 1 |
| Sapin, R | 1 |
| Poulet, P | 1 |
| Guignard, B | 1 |
| Parizel, N | 1 |
| Grucker, D | 1 |
| Boehm, N | 1 |
| Miller, RH | 1 |
| Ghandour, MS | 1 |
| Fernández, M | 2 |
| Paradisi, M | 1 |
| Del Vecchio, G | 2 |
| Giardino, L | 2 |
| Calzà, L | 2 |
| D'Intino, G | 1 |
| Lorenzini, L | 1 |
| Taglioni, A | 1 |
| Perretta, G | 1 |
| Villoslada, P | 1 |
| Rogister, B | 1 |
| Belachew, S | 1 |
| Moonen, G | 1 |
| Afshari, FS | 1 |
| Chu, AK | 1 |
| Sato-Bigbee, C | 1 |
| Matthieu, JM | 1 |
| Comte, V | 1 |
| Tosic, M | 1 |
| Honegger, P | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 1b, Open-label Study to Evaluate the Safety and Tolerability of the Putative Remyelinating Agent, Liothyronine, in Individuals With MS[NCT02506751] | Phase 1 | 20 participants (Actual) | Interventional | 2015-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for triiodothyronine and Demyelinating Diseases
| Article | Year |
|---|---|
Oligodendrocytes: from development to demyelinated lesion repair.
Topics: Cell Differentiation; Demyelinating Diseases; Disease Progression; Humans; Nerve Regeneration; Oligo | 1999 |
10 other studies available for triiodothyronine and Demyelinating Diseases
| Article | Year |
|---|---|
Thyroid hormone and thyromimetics inhibit myelin and axonal degeneration and oligodendrocyte loss in EAE.
Topics: Acetates; Animals; Demyelinating Diseases; Encephalomyelitis, Autoimmune, Experimental; Female; Mice | 2021 |
Regulatory effect of triiodothyronine on brain myelination and astrogliosis after cuprizone-induced demyelination in mice.
Topics: Animals; Brain; Cuprizone; Demyelinating Diseases; Disease Models, Animal; Gliosis; Male; Mice, Inbr | 2016 |
The effect of triiodothyronine on maturation and differentiation of oligodendrocyte progenitor cells during remyelination following induced demyelination in male albino rat.
Topics: Animals; Cell Differentiation; Corpus Callosum; Cuprizone; Demyelinating Diseases; Gene Expression R | 2016 |
A mouse model for testing remyelinating therapies.
Topics: Animals; Axons; Brain; Calcium-Binding Proteins; Cuprizone; Demyelinating Diseases; Disease Models, | 2016 |
Thyroid hormones promote differentiation of oligodendrocyte progenitor cells and improve remyelination after cuprizone-induced demyelination.
Topics: Animals; Animals, Newborn; Antigens; Blood Coagulation Factors; Cell Differentiation; Cuprizone; Dem | 2008 |
Recovery from chronic demyelination by thyroid hormone therapy: myelinogenesis induction and assessment by diffusion tensor magnetic resonance imaging.
Topics: Animals; Brain Mapping; Carbonic Anhydrase II; Chronic Disease; Cuprizone; Demyelinating Diseases; D | 2008 |
Thyroid hormone induces glial lineage of primary neurospheres derived from non-pathological and pathological rat brain: implications for remyelination-enhancing therapies.
Topics: Animals; Brain; Cell Differentiation; Cell Lineage; Cells, Cultured; Demyelinating Diseases; Encepha | 2009 |
Triiodothyronine administration ameliorates the demyelination/remyelination ratio in a non-human primate model of multiple sclerosis by correcting tissue hypothyroidism.
Topics: Animals; Biomarkers; Callithrix; Demyelinating Diseases; Disease Models, Animal; Encephalomyelitis, | 2011 |
Recovery of adult oligodendrocytes is preceded by a "lag period" accompanied by upregulation of transcription factors expressed in developing young cells.
Topics: Animals; Animals, Newborn; Blotting, Western; Cell Differentiation; Cells, Cultured; Central Nervous | 2002 |
Myelin gene expression during demyelination and remyelination in aggregating brain cell cultures.
Topics: 2',3'-Cyclic-Nucleotide Phosphodiesterases; Animals; Brain; Cattle; Cell Aggregation; Cells, Culture | 1992 |